Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma?
We discuss all that and more on a special live (to tape) episode “The Readout LOUD,” STAT’s biotech podcast. In front of a studio audience in Boston, we talk about the first glimpse at how genome editing affects actual humans and the disappointment it brought. Then we take a look at how 2018 has panned out for some of biotech’s hot-button issues, including buyouts, IPOs, and President Trump’s effect on drug prices. We also dive into former Celgene CEO Bob Hugin’s effort to win a Senate race in New Jersey at a time when his industry is widely disliked. And then we embark upon live lightning round, answering questions from members of the audience.
